Literature DB >> 24994604

Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura.

T Falter1, J A Kremer Hovinga, K Lackner, H-G Füllemann, B Lämmle, I Scharrer.   

Abstract

UNLABELLED: We report on our patient (case 2) who experienced a first acute episode of thrombotic thrombocytopenic purpura (TTP) at the age of 19 years during her first pregnancy in 1976 which ended in a spontaneous abortion in the 30th gestational week. Treatment with red blood cell concentrates was implemented and splenectomy was performed. After having suffered from several TTP episodes in 1977, possibly mitigated by acetylsalicylic acid therapy, an interruption and sterilization were performed in 1980 in her second pregnancy thereby avoiding another disease flare-up. Her elder sister (case 1) had been diagnosed with TTP in 1974, also during her first pregnancy. She died in 1977 during her second pregnancy from a second acute TTP episode. DIAGNOSIS: In 2013 a severe ADAMTS13 deficiency of <10% without detectable ADAMTS13 inhibitor was repeatedly found. Investigation of the ADAMTS13 gene showed that the severe ADAMTS13 deficiency was caused by compound heterozygous ADAMTS13 mutations: a premature stop codon in exon 2 (p.Q44X), and a missense mutation in exon 24 (p.R1060W) associated with low but measurable ADAMTS13 activity.
CONCLUSION: Genetic analysis of the ADAMTS13 gene is important in TTP patients of all ages if an ADAMTS13 inhibitor has been excluded.

Entities:  

Keywords:  ADAMTS13 activity; ADAMTS13 mutation; Hereditary TTP; pregnancy

Mesh:

Substances:

Year:  2014        PMID: 24994604     DOI: 10.5482/HAMO-14-03-0023

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  1 in total

1.  Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Louis Deforche; Claudia Tersteeg; Elien Roose; Aline Vandenbulcke; Nele Vandeputte; Inge Pareyn; Elien De Cock; Hanspeter Rottensteiner; Hans Deckmyn; Simon F De Meyer; Karen Vanhoorelbeke
Journal:  PLoS One       Date:  2016-08-01       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.